STOK
Stoke Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$27.68-4.72%
Price as of Jul 20, 2026
STOK growth
Stoke Therapeutics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -83.2%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
- Revenue
- +16.9%
- EBITDA
- +95.4%
- EPS
- -16.3%
Three-year CAGR
- Revenue
- +145.9%
- EBITDA
- +94.1%
- EBIT
- +79.7%
- Net income
- +92.3%
- EPS
- +92.7%
- Free cash flow
- +151.6%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.